<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref163">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Wu</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Pfarr</surname>
    <given-names>D. S.</given-names>
   </name>
   <name>
    <surname>Johnson</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Brewah</surname>
    <given-names>Y. A.</given-names>
   </name>
   <name>
    <surname>Woods</surname>
    <given-names>R. M.</given-names>
   </name>
   <name>
    <surname>Patel</surname>
    <given-names>N. K.</given-names>
   </name>
   <etal/>
  </person-group>. (
  <year>2007</year>). 
  <article-title>Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract</article-title>. 
  <source>J. Mol. Biol.</source>
  <volume>368</volume>, 
  <fpage>652</fpage>â€“
  <lpage>665</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.jmb.2007.02.024</pub-id>, PMID: 
  <?supplied-pmid 17362988?>
  <pub-id pub-id-type="pmid">17362988</pub-id>
 </mixed-citation>
</ref>
